Document is current
Any future updates will be listed below
-
Authors
Earla, Jagadeswara R. https://orcid.org/0000-0002-6688-5273
Kurian, Allison W.
Kponee-Shovein, Kalé
Mahendran, Malena
Song, Yan
Hua, Qi
Hilts, Annalise
Sun, Yezhou
Hirshfield, Kim M.
Robson, Mark
Mejia, Jaime A.
-
Funding
Funding for this research was provided by:
Merck Sharpe & Dohme LLC, a subsidiary of Merck & Co, Inc.
AstraZeneca UK Ltd
- License Information
-
More Information
Article History
Received: 20 September 2024
Accepted: 18 November 2024
First Online: 16 December 2024
Declarations
:
: Jagadeswara R. Earla, Yezhou Sun, Kim M. Hirshfield, and Jaime A. Mejia are employees and stockholders of Merck & Co., Inc. Allison W. Kurian does not have any conflicts of interest to disclose. Kalé Kponee-Shovein, Malena Mahendran, Yan Song, Qi Hua, and Annalise Hilts are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Merck & Co., Inc., which funded the development and conduct of this study and manuscript. Mark Robson reports the following conflicts of interest: advisory board/consulting (uncompensated) for Artios Pharma, AstraZeneca, GlaxoSmithKline, MSD, Pfizer, Tempus Labs, and Zenith Pharma; research funding (to institution) from Artios Pharma, AstraZeneca, and MSD; travel support from AstraZeneca; and other payments (editorial support) from AstraZeneca and Pfizer.
: The authors received permission to access and use de-identified SEER cancer registry data linked to Medicare administrative claims data from the National Cancer Institute. This study was reviewed by the Advarra IRB (Pro00055299), and received an exemption from oversight on August 26, 2021, in accordance with the Department of Health and Human Services regulations found at 45 CFR 46.104(d)(4).
